Credit Suisse AG raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 36.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 354,797 shares of the medical equipment provider’s stock after acquiring an additional 95,405 shares during the period. Credit Suisse AG owned approximately 0.13% of Hologic worth $14,541,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. Piedmont Investment Advisors LLC purchased a new stake in shares of Hologic in the second quarter worth $127,000. Bessemer Group Inc. grew its stake in shares of Hologic by 122.4% in the third quarter. Bessemer Group Inc. now owns 3,534 shares of the medical equipment provider’s stock worth $145,000 after acquiring an additional 1,945 shares during the last quarter. Amussen Hunsaker Associates LLC purchased a new stake in shares of Hologic in the second quarter worth $159,000. Stratos Wealth Partners LTD. purchased a new stake in shares of Hologic in the third quarter worth $185,000. Finally, Lincoln Capital Corp purchased a new stake in shares of Hologic during the third quarter valued at $201,000. 91.73% of the stock is currently owned by hedge funds and other institutional investors.

In other Hologic news, SVP Allison P. Bebo sold 6,500 shares of the stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $42.00, for a total value of $273,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christiana Stamoulis sold 13,257 shares of the stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $44.50, for a total value of $589,936.50. Following the completion of the transaction, the director now directly owns 48,296 shares in the company, valued at approximately $2,149,172. The disclosure for this sale can be found here. In the last three months, insiders sold 79,276 shares of company stock worth $3,311,802. 0.79% of the stock is owned by corporate insiders.

HOLX stock opened at $43.90 on Thursday. Hologic, Inc. has a fifty-two week low of $35.10 and a fifty-two week high of $45.17. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.95 and a current ratio of 1.23. The stock has a market capitalization of $12.70 billion, a price-to-earnings ratio of 19.60, a PEG ratio of 2.03 and a beta of 0.69.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.01). Hologic had a negative net margin of 3.46% and a positive return on equity of 23.52%. The firm had revenue of $813.50 million during the quarter, compared to the consensus estimate of $808.63 million. During the same period in the prior year, the company posted $0.50 EPS. The firm’s revenue was up 1.3% compared to the same quarter last year. On average, equities analysts predict that Hologic, Inc. will post 2.4 earnings per share for the current year.

Several equities research analysts recently commented on HOLX shares. BidaskClub raised Hologic from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 19th. Bank of America cut Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $47.00 to $42.00 in a research report on Thursday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $48.00 price objective on shares of Hologic in a research report on Thursday, September 27th. Canaccord Genuity dropped their price objective on Hologic from $41.00 to $40.00 and set a “hold” rating on the stock in a research report on Thursday, September 13th. Finally, Morgan Stanley dropped their price objective on Hologic from $47.00 to $44.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 11th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $44.53.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/credit-suisse-ag-buys-95405-shares-of-hologic-inc-holx/2664182.html.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Article: Federal Reserve

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.